Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | CA209-9KY: IMRT + nivolumab for recurrent head and neck squamous cell cancer

Nabil F. Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the CA209-9KY trial (NCT03521570), which investigated the efficacy of intensity-modulated radiotherapy (IMRT) and nivolumab in treating patients with recurrent head and neck squamous cell cancer (HNSCC). After one year, the progression-free survival was 57.8%, and the overall survival was 81.7%. There were also very few severe treatment-related adverse events (AEs), with the most common AEs being fatigue, dermatitis and dysphagia. Hence, IMRT reirradiation with concurrent and adjuvant nivolumab was clinically effective and well-tolerated in patients with HNSCC. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.